Abstract. – Background: Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers.
Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.
Results and Conclusions: Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
Corresponding Author: Giovanni Paganelli, MD; e-mail: firstname.lastname@example.orgFree PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
L. Bodei, G. Pepe, G. Paganelli
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
Eur Rev Med Pharmacol Sci
Vol. 14 - N. 4